End-organ recovery is key to success for extracorporeal membrane oxygenation as a bridge to implantable left ventricular assist device

Joel B. Durinka, Linda J. Bogar, Hitoshi Hirose, Christoph Brehm, Michael M. Koerner, Walter Pae, Aly El-Banayosy, Edward Stephenson, Nicholas C. Cavarocchi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Preexisting organ dysfunctions are known factors of death after placement of implantable mechanical circulatory support (MCS). Extracorporeal membrane oxygenation (ECMO) may able to stabilize organ function in patients with cardiogenic shock before MCS implantation. Between 2008 and 2012, 17 patients with cardiogenic shock were supported with ECMO before implantable MCS placement. Patient's end-organ functions were assessed by metabolic, cardiac, hepatic, renal, and respiratory parameters. Survival data after MCS implantations were analyzed for overall survival to discharge, complications, and breakpoint in days on ECMO to survival. Before MCS implantation, lactate, hepatic, and renal functions were improved and pulmonary edema was resolved. The interval between ECMO initiation and MCS placement was 12.1 ± 7.9 days. Overall survival rate to discharge after left ventricular assist device/total artificial heart placement was 76%. The survival of patients transitioned from ECMO to MCS within 14 days was 92% and was significantly better than the survival of patients from ECMO to MCS supported longer than 14 days, 25%, p < 0.05. ECMO support can immediately stabilize organ dysfunction in patients with cardiogenic shock. After improvement of organ function, MCS implantation should be done without delay, since the patients supported for longer than 14 days with ECMO had inferior survival compared to national data.

Original languageEnglish (US)
Pages (from-to)189-192
Number of pages4
JournalASAIO Journal
Volume60
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Left ventricular assist devices
Extracorporeal Membrane Oxygenation
Heart-Assist Devices
Oxygenation
Membranes
Recovery
Survival
Cardiogenic Shock
Artificial heart
Kidney
Artificial Heart
Liver
Pulmonary Edema
Lactic Acid
Survival Rate

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Biophysics
  • Medicine(all)
  • Biomaterials
  • Biomedical Engineering

Cite this

Durinka, Joel B. ; Bogar, Linda J. ; Hirose, Hitoshi ; Brehm, Christoph ; Koerner, Michael M. ; Pae, Walter ; El-Banayosy, Aly ; Stephenson, Edward ; Cavarocchi, Nicholas C. / End-organ recovery is key to success for extracorporeal membrane oxygenation as a bridge to implantable left ventricular assist device. In: ASAIO Journal. 2014 ; Vol. 60, No. 2. pp. 189-192.
@article{a1bc06b3ee634c3caab98f7dd6a91098,
title = "End-organ recovery is key to success for extracorporeal membrane oxygenation as a bridge to implantable left ventricular assist device",
abstract = "Preexisting organ dysfunctions are known factors of death after placement of implantable mechanical circulatory support (MCS). Extracorporeal membrane oxygenation (ECMO) may able to stabilize organ function in patients with cardiogenic shock before MCS implantation. Between 2008 and 2012, 17 patients with cardiogenic shock were supported with ECMO before implantable MCS placement. Patient's end-organ functions were assessed by metabolic, cardiac, hepatic, renal, and respiratory parameters. Survival data after MCS implantations were analyzed for overall survival to discharge, complications, and breakpoint in days on ECMO to survival. Before MCS implantation, lactate, hepatic, and renal functions were improved and pulmonary edema was resolved. The interval between ECMO initiation and MCS placement was 12.1 ± 7.9 days. Overall survival rate to discharge after left ventricular assist device/total artificial heart placement was 76{\%}. The survival of patients transitioned from ECMO to MCS within 14 days was 92{\%} and was significantly better than the survival of patients from ECMO to MCS supported longer than 14 days, 25{\%}, p < 0.05. ECMO support can immediately stabilize organ dysfunction in patients with cardiogenic shock. After improvement of organ function, MCS implantation should be done without delay, since the patients supported for longer than 14 days with ECMO had inferior survival compared to national data.",
author = "Durinka, {Joel B.} and Bogar, {Linda J.} and Hitoshi Hirose and Christoph Brehm and Koerner, {Michael M.} and Walter Pae and Aly El-Banayosy and Edward Stephenson and Cavarocchi, {Nicholas C.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/MAT.0000000000000043",
language = "English (US)",
volume = "60",
pages = "189--192",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

End-organ recovery is key to success for extracorporeal membrane oxygenation as a bridge to implantable left ventricular assist device. / Durinka, Joel B.; Bogar, Linda J.; Hirose, Hitoshi; Brehm, Christoph; Koerner, Michael M.; Pae, Walter; El-Banayosy, Aly; Stephenson, Edward; Cavarocchi, Nicholas C.

In: ASAIO Journal, Vol. 60, No. 2, 01.01.2014, p. 189-192.

Research output: Contribution to journalArticle

TY - JOUR

T1 - End-organ recovery is key to success for extracorporeal membrane oxygenation as a bridge to implantable left ventricular assist device

AU - Durinka, Joel B.

AU - Bogar, Linda J.

AU - Hirose, Hitoshi

AU - Brehm, Christoph

AU - Koerner, Michael M.

AU - Pae, Walter

AU - El-Banayosy, Aly

AU - Stephenson, Edward

AU - Cavarocchi, Nicholas C.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Preexisting organ dysfunctions are known factors of death after placement of implantable mechanical circulatory support (MCS). Extracorporeal membrane oxygenation (ECMO) may able to stabilize organ function in patients with cardiogenic shock before MCS implantation. Between 2008 and 2012, 17 patients with cardiogenic shock were supported with ECMO before implantable MCS placement. Patient's end-organ functions were assessed by metabolic, cardiac, hepatic, renal, and respiratory parameters. Survival data after MCS implantations were analyzed for overall survival to discharge, complications, and breakpoint in days on ECMO to survival. Before MCS implantation, lactate, hepatic, and renal functions were improved and pulmonary edema was resolved. The interval between ECMO initiation and MCS placement was 12.1 ± 7.9 days. Overall survival rate to discharge after left ventricular assist device/total artificial heart placement was 76%. The survival of patients transitioned from ECMO to MCS within 14 days was 92% and was significantly better than the survival of patients from ECMO to MCS supported longer than 14 days, 25%, p < 0.05. ECMO support can immediately stabilize organ dysfunction in patients with cardiogenic shock. After improvement of organ function, MCS implantation should be done without delay, since the patients supported for longer than 14 days with ECMO had inferior survival compared to national data.

AB - Preexisting organ dysfunctions are known factors of death after placement of implantable mechanical circulatory support (MCS). Extracorporeal membrane oxygenation (ECMO) may able to stabilize organ function in patients with cardiogenic shock before MCS implantation. Between 2008 and 2012, 17 patients with cardiogenic shock were supported with ECMO before implantable MCS placement. Patient's end-organ functions were assessed by metabolic, cardiac, hepatic, renal, and respiratory parameters. Survival data after MCS implantations were analyzed for overall survival to discharge, complications, and breakpoint in days on ECMO to survival. Before MCS implantation, lactate, hepatic, and renal functions were improved and pulmonary edema was resolved. The interval between ECMO initiation and MCS placement was 12.1 ± 7.9 days. Overall survival rate to discharge after left ventricular assist device/total artificial heart placement was 76%. The survival of patients transitioned from ECMO to MCS within 14 days was 92% and was significantly better than the survival of patients from ECMO to MCS supported longer than 14 days, 25%, p < 0.05. ECMO support can immediately stabilize organ dysfunction in patients with cardiogenic shock. After improvement of organ function, MCS implantation should be done without delay, since the patients supported for longer than 14 days with ECMO had inferior survival compared to national data.

UR - http://www.scopus.com/inward/record.url?scp=84896396416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896396416&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000043

DO - 10.1097/MAT.0000000000000043

M3 - Article

C2 - 24399062

AN - SCOPUS:84896396416

VL - 60

SP - 189

EP - 192

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 2

ER -